ESE.S. Shelepova

E.S. Shelepova

*This is an algorithmically generated author record based on publicly available information.

E.S. Shelepova has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • TSH and β-hCG levels in patients with placenta accreta spectrum

    by A.A. Kuznetsova, Saint Petersburg 2B Akkuratova Str., E.S. Shelepova, K.A. Alfimova, O.I. Labushnyak, N.A. Osipova, I.E. Zazerskaya

    Aim. To assess the concentration of thyroid-stimulating hormone and human chorionic gonadotropin in pregnant women with placenta accreta spectrum. Design. Longitudinal prospective case-control study. Materials and methods. The study included 161 patients with placenta accreta spectrum (main group further devided in accordance with presence of ceserian ssction (CS) scar (subgroup 1.1 with CS scar present, n = 143 and subgroup 1.2 with CS scar absent, n = 18), 126 patients previously underwent cesarean section (comparison group 1), and 36 healthy patients (comparison group 1). Patients in all groups were further divided by the presence of established thyroid pathology. A comparative analysis was performed to evaluate thyroid-stimulating hormone levels during pregnancy and human chorionic gonadotropin levels based on the first timester screening. Results. According to the study results, among patients without thyroid pathology, a significant decrease of thyroid stimulating hormone was noted in the 1st and 3rd trimesters in main group, relative to comparison groups (p1.1–1 = 0.019; 0.014; p1.2–2 = 0.03; 0.024). No significant difference in the levels of human chorionic gonadotropin was found in the groups (both absolute and standardized values (abs/MoM)) (p1.1–1 = 0.863/0.591; p1.2–2 = 0.286/0.987). The concentration of thyroid stimulating hormone in the 1st trimester significantly correlated with placenta previa (p1.1–1 = 0.009; p1.2–2 = 0.036). The average daily dosage of levothyroxine sodium in the main group was significantly higher than in the comparison groups (p1 = 0.007; p2 = 0.006). Conclusion. Thyroid-stimulating hormone levels in the first and third trimesters in patients without established thyroid pathology are reduced and correlate with the presence of placenta accreta spectrum. Meanwhile, patients with placenta accreta require higher doses of hormone replacement therapy during pregnancy, with no significant correlation between thyroid-stimulating hormone levels and the presence of this complication. Keywords: placenta accreta spectrum, TSH, hCG.

  • Prognostic risk factors for abnormally adherent and invasive placenta in women with placenta located in the area of the uterine scar

    by N.YU. Ponikarova, Saint Petersburg 2B Akkuratova Str., E.S. Shelepova, A.A. Kazanskaya, V.N. Kustarov, I.E. Zazerskaya

    Aim. To identify independent prognostic risk factors for abnormally adherent and invasive placenta (AAIP) in women with a placenta located in the area of a uterine scar. Design. Case-control study. Materials and methods. A study was conducted involving 110 women with placenta located in the area of a uterine scar, divided into two groups: the main group with placenta located in the area of the uterine scar and abnormally adherent and invasive placenta (AAIP) (n = 55) and the control group with placenta located in the area of the uterine scar without AAIP (n = 55). A retrospective analysis was performed using medical records, general and obstetric examination data, and information collected during pregnancy and at the time of hospitalization for delivery. Statistical analysis methods were used to identify significant factors. Results. Despite comparable obstetric and gynecological history, the key prognostic factors for AAIP were features of the current pregnancy: placenta previa (odds ratio (OR) = 70.7; 95% confidence interval (CI) 15.3–326.8); vaginal bleeding after 26 weeks of gestation (OR = 5.7; 95% CI 2.47–12.97); threatened late miscarriage/preterm birth in the 2nd and 3rd trimesters (OR = 4.3 and 3.5, respectively); anemia diagnosed in the 2nd trimester (OR = 2.66; 95% CI 1.2–6.1). Conclusion. In women with placenta located in the area of the uterine scar, in addition to placenta previa, independent prognostic risk factors for AAIP are late-pregnancy bleeding, threatened preterm birth in the 2nd–3rd trimesters, and 2nd-trimester anemia. The establishment of these features will improve the prenatal detection of high-risk patients. Keywords: abnormally adherent and invasive placenta, placenta located in the uterine scar, risk factors, placenta previa, obstetric hemorrhage.